


ORIGINAL CASE STUDY

Available online at http://www.journalijdr.com



International Journal of Development Research Vol. 07, Issue, 10, pp.15844-15845, October, 2017



OPEN ACCESS

CASE REPORT- FATEL CASE OF RABIES

Dr. Priyanka Kashyap and *Dr. Sunil Bhatt

Shri Mehant Indresh Hospital, Dehradun, Uttrakhand, India

Rabies is an acute viral encephalomyelitis that is almost invariably Fatal. It is caused by

rhabdovirus of the genus Lyssavirus and is endemic in wild and domestic animals in many parts

of the world. Areas with high risk of human infection are south- and south-east Asia (Nepal,

India), but regions with increased risk also exist in Africa, South America and Eastern Europe. In

this article we describe the clinical presentation of a Fatal case of rabies in a young adult of 24 yrs

ABSTRACT

old

ARTICLE INFO

Article History: Received 19th July, 2017 Received in revised form 05th August, 2017 Accepted 27th September, 2017 Published online 10th October, 2017

Keywords:

Rabies, Fatal Disease. Vaccine, Antibody.

*Corresponding author

Copyright ©2017, Dr. Priyanka Kashyap and Dr. Sunil Bhatt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Priyanka Kashyap and Dr. Sunil Bhatt. 2017. "Case report- Fatel case of rabies", International Journal of Development Research, 7, (09), 15844-15845.

INTRODUCTION

On 20 April 2016, a 24 year-old male was referred to our hospital Shri Mehant Indresh Hospital from Saharanpur District of UP. He had been bitten in his left leg by a stray dog in Saharanpur four weeks previously. He sought medical assistance in Saharanpur immediately after the incident. Rabies vaccination was not initiated at that time. His symptoms started on 15 April (day 1) with paraesthesia and severe pain in the left leg. The patient presented at a local hospital in Saharanpur on 16 April with fever, nausea, paraesthesia of the left leg, headache and difficulties in swallowing. On the basis of the anamnesis, a rabies infection was suspected, and vaccination was immediately started according to the World Health Organization (WHO) rabies postexposure prophylaxis (PEP) protocol (Rupprecht et al., 2002) with purified chicken embryo cell vaccine (PCECV, Rabipur, Behring, "Essen-scheme") and anti-rabies hyperimmunoglobuline (HRIG, Berirab, Behring; 20mg/kg).

Treatment and clinical course

Five days after the onset of illness, the patient was transferred to our hospital Shri Mehant Indresh Hospital. A heminested RT-PCR for rabies virus nucleocapsid RNA from two different

saliva samples and one corneal swab that was initiated on the same day, was positive. Antibodies against rabies virus could not be detected in the serum or in the cerebrospinal fluid (CSF), neither by indirect immunofluorescence test (IIFT) nor by ELISA. Patient developed continous seizures in our hospital which relieved were not by anti epileptics. Subsequently, deep analgosedation with ketamine, midazolam and respirator therapy was initiated on day six. Except for amantadine, no other antiviral drugs were given. The patient was enterally nourished, and low molecular prophylactic heparin dosage in а was initiated. Electroencephalography (EEG), did not show significant pathology. Until eight days after onset of symptoms, no rabies virus antibodies were detectable in serum and cerebrospinal fluid. In order to support seroconversion of the patient, a live attenuated rabies virus vaccine (VirBac, Nice) was administered intradermally. On day 11, increasing rabies virus antibodies were detectable by IIFT in the serum, but not in the CSF. A revaccination with the same vaccine was given on day 15 in the hope to induce an earlier antibody response. On day 20, we were able to detect an early antibody response in the CSF also. On day 21 the patient developed pathologically raised blood pressure, his pupils became wide, non-reacting and oval.

No electrical brain activity could be detected by EEG from day 22 onwards. Whether the suppression of electrical brain activity was due to the high dose of sedative drugs or to brain damage caused by the virus is uncertain, and therefore could not be interpreted as a sign of brain death (De Tourtchaninoff et al., 1999). The patient was continuously on ketamine for its postulated antiviral potency, even after EEG monitoring showed no electrical brain activity. This therapy was not discontinued because transient EEG findings conclusive with brain death had been described before in the single survivor of a rabies infection (Willoughby, 2007; Willoughby, 2005; Rupprecht et al., 2002; CDC, 2004). An MRI scan on day 29 showed a generalised oedema of the whole cortex and the basal ganglia. Although ultrasound examination displayed a normal heart function, the patient developed ventricular arrhytmia before death. He died on day 31 after first onset of symptoms from multi-organ failure.

DISCUSSION

To date there has been only one report of a recovery of a patient with a human rabies infection (CDC, 2004). The therapeutic strategy that had initially been chosen in this case, had failed in other patients. We therefore felt that we had to modify our therapy. We analysed the transplantationassociated rabies cases in Germany in 2005, a treatment trial of a patient in Thailand 2006, and the case of the rabies survivor in Wisconsin, and developed a vaccine strategy that was aimed at inducing an early antibody response. We administered the vaccine intradermally, hoping to achieve better antigen presentation and response in the skin. In addition, this gave us the opportunity to monitor immune response and viral load in skin biopsies. The concept of deep analgosedation with ketamine was chosen because of a lack treatment alternatives and drugs with the potential to suppress viral spread in tissue cultures, even though this had failed in other treatment trials. Ribavirin was not given due to its lack of anti-rabies activity and its potential to delay cellular immunity (Warrell et al., 1989).

Despite the fact that we were able to detect an early antibody response in the serum, and later in the CSF, the viral spread in the brain tissue could not be stopped. Since the experiences made in the case of the single survivor were not able to improve the outcome of other cases treated similarly, human rabies infections must still be viewed as always Fatal. We tried to induce anti-rabies antibody production earlier in the course of illness with the idea to have an immune response against virus infected nerve cells before all neurons are infected. In our patient, this strategy failed.

REFERENCES

- Centers for Disease Control and Prevention (CDC), 2004. Recovery of a patient from clinical rabies--Wisconsin, MMWR Morb Mortal Wkly Rep 2004;53(50):1171-3. Available from: http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5350a1.htm
- De Tourtchaninoff, M., Hantson, P., Mahieu, P. and Guerit, J.M. 1999. Brain death diagnosis in misleading conditions. QJM Jul;92(7):407-14.
- Rupprecht, C.E., Hanlon, C.A. and Hemachudha, T. 2002. Rabies re-examined. Lancet Infect Dis Jun;2(6):327-43.
- Warrell, M.J., White, N.J., Looareesuwan, S., Phillips, R.E., Suntharasamai, P., Chanthavanich, P., *et al.* 1989. Failure of interferon alfa and tribavirin in rabies encephalitis. *BMJ*, Sep 30;299(6703):830-3.
- Willoughby, R.E. Jr, Tieves, K.S., Hoffman, G.M., Ghanayem, N.S., Amlie-Lefond, C.M., Schwabe, M.J., *et al.* 2005. Survival after treatment of rabies with induction of coma. *N Engl J Med*, Jun 16;352(24):2508-14.
- Willoughby, R.E. Jr. 2007. A cure for a rabies? *Sci Am*, Apr; 296(4):88-95.
